AlloVir Inc (ALVR)
0.781
-0.04
(-4.34%)
USD |
NASDAQ |
May 10, 16:00
0.781
0.00 (0.00%)
After-Hours: 20:00
AlloVir Cash from Investing (TTM): 37.98M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 37.98M |
September 30, 2023 | 26.30M |
June 30, 2023 | 54.60M |
March 31, 2023 | 16.22M |
December 31, 2022 | -80.48M |
September 30, 2022 | -107.54M |
June 30, 2022 | -14.01M |
March 31, 2022 | 66.18M |
December 31, 2021 | 185.98M |
Date | Value |
---|---|
September 30, 2021 | 201.43M |
June 30, 2021 | -63.80M |
March 31, 2021 | -118.51M |
December 31, 2020 | -169.50M |
September 30, 2020 | -136.54M |
June 30, 2020 | 73.77M |
March 31, 2020 | -50.80M |
December 31, 2019 | -64.64M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-169.50M
Minimum
Dec 2020
201.43M
Maximum
Sep 2021
-8.433M
Average
-14.01M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
CEL-SCI Corp | -0.3835M |
AIM ImmunoTech Inc | -0.832M |
IGC Pharma Inc | -0.236M |
NovaBay Pharmaceuticals Inc | -0.019M |
Protalix BioTherapeutics Inc | -16.71M |